The Experts below are selected from a list of 918 Experts worldwide ranked by ideXlab platform

Hartmut Lode - One of the best experts on this subject based on the ideXlab platform.

  • pharmacokinetics of gatifloxacin and interaction with an antacid containing Aluminum and Magnesium
    Antimicrobial Agents and Chemotherapy, 1999
    Co-Authors: Silke Lober, Susanne Ziege, Gabriele Schreiber, Alain Mignot, Peter Koeppe, Hartmut Lode
    Abstract:

    The pharmacokinetics of gatifloxacin (400 mg orally) and the influence of the antacid Aluminum Magnesium Hydroxide (20 ml of Maalox 70) on the bioavailability of gatifloxacin in 24 healthy volunteers were assessed. In an open, randomized, six-period crossover study, the volunteers received either gatifloxacin alone (treatments A and D); Aluminum Magnesium Hydroxide concomitant with gatifloxacin (treatment C); or Aluminum Magnesium Hydroxide 2 h before (treatment B), 2 h after (treatment E), or 4 h after gatifloxacin administration (treatment F). Gatifloxacin concentrations were measured by a validated bioassay and high-performance liquid chromatography. Pharmacokinetics of a single 400-mg dose of gatifloxacin alone were characterized as follows (mean ± standard deviation): peak concentration ( C max ), 3.8 ± 0.5 (treatment A) and 3.4 ± 0.9 (treatment D) μg/ml; time to C max , 1.4 ± 0.8 (treatment A) and 1.7 ± 0.7 (treatment D) h; area under the curve from time zero to infinity (AUC 0–∞ ), 33.5 ± 5.9 (treatment A) and 31.4 ± 3.4 (treatment D) μg · h/ml; urine recovery, (83 ± 6)% (treatment A) and (84 ± 8)% (treatment D). Comparison of the results obtained by bioassay showed a good correlation. Aluminum Magnesium Hydroxide administration 2 h before (treatment B) or concomitant with (treatment C) gatifloxacin decreased the C max by 45% (2.1 ± 1.2 μg/ml) or even 68% (1.2 ± 0.4 μg/ml) highly significantly ( P 0–∞ was significantly reduced from 33.5 ± 5.9 to 19.4 ± 6.9 μg · h/ml (by 42%) or even to 11.9 ± 3.3 μg · h/ml (by 64%) ( P 0–∞ was significantly reduced from 31.4 ± 3.4 to 25.9 ± 5.3 μg · h/ml (18%) ( P

  • Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist.
    Antimicrobial Agents and Chemotherapy, 1992
    Co-Authors: N. Saathoff, Hartmut Lode, K Neider, K M Depperman, Klaus Borner, Peter Koeppe
    Abstract:

    Cefpodoxime proxetil is a new oral esterified cephem antibiotic with a broad antibacterial spectrum. The dissolution of cefpodoxime proxetil is pH dependent. The objectives of this study were to characterize the pharmacokinetics of cefpodoxime proxetil in two different oral doses and to examine possible interactions with an antacid, Aluminum Magnesium Hydroxide (Maalox 70), and an H2 receptor antagonist, famotidine. Two studies involving the same 10 healthy volunteers were performed. In the first study, cefpodoxime proxetil was administered in two doses, 0.1 and 0.2 g. In the second study, two interventions were performed in a randomized crossover design. For one intervention, the volunteers were pretreated with 40 mg of famotidine 1 h before 0.2 g of cefpodoxime proxetil was administered. In the second trial, participants were given 10 ml of Maalox 70 2 h and 10 ml of Maalox 70 15 min before they received 0.2 g of cefpodoxime proxetil. Serum and urine concentrations were determined by high-performance liquid chromatography. For the statistical evaluation, these data were tested by using the pharmacokinetics of 0.2 g of cefpodoxime proxetil from the first study. The maximum concentrations were 1.19 +/- 0.32 mg/liter after 0.1 g of cefpodoxime proxetil and 2.54 +/- 0.64 mg/liter after 0.2 g of cefpodoxime proxetil. The elimination half-lives were 149 min for 0.1 g and 172 min for 0.2 g of cefpodoxime proxetil. The total increase in the area under the concentration-time curve (AUC) was dose dependent. Combination with Maalox 70 caused a reduction in the AUC from 14.0 +/- 3.9 to 8.44 +/- 1.85 mg.h/liter. After famotidine, the AUC decreased to 8.36 +/- 2.0 mg . h/liter. Corresponding changes were registered for the maximum concentration of drug in serum, 24-h urine recovery, and the time to maximum concentration of drug serum. Cefpodoxime proxetil was well tolerated without any seriously adverse drug reactions.

Peter Koeppe - One of the best experts on this subject based on the ideXlab platform.

  • pharmacokinetics of gatifloxacin and interaction with an antacid containing Aluminum and Magnesium
    Antimicrobial Agents and Chemotherapy, 1999
    Co-Authors: Silke Lober, Susanne Ziege, Gabriele Schreiber, Alain Mignot, Peter Koeppe, Hartmut Lode
    Abstract:

    The pharmacokinetics of gatifloxacin (400 mg orally) and the influence of the antacid Aluminum Magnesium Hydroxide (20 ml of Maalox 70) on the bioavailability of gatifloxacin in 24 healthy volunteers were assessed. In an open, randomized, six-period crossover study, the volunteers received either gatifloxacin alone (treatments A and D); Aluminum Magnesium Hydroxide concomitant with gatifloxacin (treatment C); or Aluminum Magnesium Hydroxide 2 h before (treatment B), 2 h after (treatment E), or 4 h after gatifloxacin administration (treatment F). Gatifloxacin concentrations were measured by a validated bioassay and high-performance liquid chromatography. Pharmacokinetics of a single 400-mg dose of gatifloxacin alone were characterized as follows (mean ± standard deviation): peak concentration ( C max ), 3.8 ± 0.5 (treatment A) and 3.4 ± 0.9 (treatment D) μg/ml; time to C max , 1.4 ± 0.8 (treatment A) and 1.7 ± 0.7 (treatment D) h; area under the curve from time zero to infinity (AUC 0–∞ ), 33.5 ± 5.9 (treatment A) and 31.4 ± 3.4 (treatment D) μg · h/ml; urine recovery, (83 ± 6)% (treatment A) and (84 ± 8)% (treatment D). Comparison of the results obtained by bioassay showed a good correlation. Aluminum Magnesium Hydroxide administration 2 h before (treatment B) or concomitant with (treatment C) gatifloxacin decreased the C max by 45% (2.1 ± 1.2 μg/ml) or even 68% (1.2 ± 0.4 μg/ml) highly significantly ( P 0–∞ was significantly reduced from 33.5 ± 5.9 to 19.4 ± 6.9 μg · h/ml (by 42%) or even to 11.9 ± 3.3 μg · h/ml (by 64%) ( P 0–∞ was significantly reduced from 31.4 ± 3.4 to 25.9 ± 5.3 μg · h/ml (18%) ( P

  • Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist.
    Antimicrobial Agents and Chemotherapy, 1992
    Co-Authors: N. Saathoff, Hartmut Lode, K Neider, K M Depperman, Klaus Borner, Peter Koeppe
    Abstract:

    Cefpodoxime proxetil is a new oral esterified cephem antibiotic with a broad antibacterial spectrum. The dissolution of cefpodoxime proxetil is pH dependent. The objectives of this study were to characterize the pharmacokinetics of cefpodoxime proxetil in two different oral doses and to examine possible interactions with an antacid, Aluminum Magnesium Hydroxide (Maalox 70), and an H2 receptor antagonist, famotidine. Two studies involving the same 10 healthy volunteers were performed. In the first study, cefpodoxime proxetil was administered in two doses, 0.1 and 0.2 g. In the second study, two interventions were performed in a randomized crossover design. For one intervention, the volunteers were pretreated with 40 mg of famotidine 1 h before 0.2 g of cefpodoxime proxetil was administered. In the second trial, participants were given 10 ml of Maalox 70 2 h and 10 ml of Maalox 70 15 min before they received 0.2 g of cefpodoxime proxetil. Serum and urine concentrations were determined by high-performance liquid chromatography. For the statistical evaluation, these data were tested by using the pharmacokinetics of 0.2 g of cefpodoxime proxetil from the first study. The maximum concentrations were 1.19 +/- 0.32 mg/liter after 0.1 g of cefpodoxime proxetil and 2.54 +/- 0.64 mg/liter after 0.2 g of cefpodoxime proxetil. The elimination half-lives were 149 min for 0.1 g and 172 min for 0.2 g of cefpodoxime proxetil. The total increase in the area under the concentration-time curve (AUC) was dose dependent. Combination with Maalox 70 caused a reduction in the AUC from 14.0 +/- 3.9 to 8.44 +/- 1.85 mg.h/liter. After famotidine, the AUC decreased to 8.36 +/- 2.0 mg . h/liter. Corresponding changes were registered for the maximum concentration of drug in serum, 24-h urine recovery, and the time to maximum concentration of drug serum. Cefpodoxime proxetil was well tolerated without any seriously adverse drug reactions.

B I Yanjun - One of the best experts on this subject based on the ideXlab platform.

  • study on adsorption and decolorization capabilities of Aluminum Magnesium Hydroxide sol
    Environmental Chemistry, 2005
    Co-Authors: B I Yanjun
    Abstract:

    The adsorption of dyes on Aluminum-Magnesium Hydroxide sol possessing permanent positive charges and effects of the molar ratio of Al/ Mg in mixed solution, the types of dyes, pH were studied.Aluminum-~Magnesium Hydroxide sol was found to be effective at removing dyes.The molar ratio of Al/ Mg in mixed solution ~1∶3 was the most effective.With the increase of pH, the adsorption of dyes decreased.Aluminum-Magnesium Hydroxide sol demonstrated a propensity to remove anionic dyes.The saturated adsorption of anionic dyes in test were 961—3319 mg·g~-1 .The increase of temperature may reduce the adsorption of dyes, which indicates that the adsorption processes studied are exothermic.

Wolfgang Mueck - One of the best experts on this subject based on the ideXlab platform.

  • effect of food an antacid and the h2 antagonist ranitidine on the absorption of bay 59 7939 rivaroxaban an oral direct factor xa inhibitor in healthy subjects
    The Journal of Clinical Pharmacology, 2006
    Co-Authors: Dagmar Kubitza, Michael Becka, Michael Zuehlsdorf, Wolfgang Mueck
    Abstract:

    To investigate the influence of food and administration of an antacid (Aluminum-Magnesium Hydroxide) or ranitidine on the absorption of BAY 59-7939 (rivaroxaban), 4 randomized studies were performed in healthy male subjects. In 2 food interaction studies, subjects received BAY 59-7939, either as two 5-mg tablets (fasted and fed), four 5-mg tablets (fasted), or one 20-mg tablet (fasted and fed). In 2 drug interaction studies, BAY 59-7939 (six 5-mg tablets) was given alone or with ranitidine (150 mg twice daily, preceded by a 3-day pretreatment phase) or antacid (10 mL). Plasma samples were obtained to assess pharmacokinetic and pharmacodynamic parameters of BAY 59-7939. In the presence of food, time to maximum concentration (t(max)) was delayed by 1.25 hours; maximum concentration (C(max)) and area under the curve (AUC) were increased, with reduced interindividual variability at higher doses of BAY 59-7939. Compared with baseline, BAY 59-7939 resulted in a relative increase in maximum prothrombin time (PT) prolongation of 44% (10 mg) and 53% (20 mg) in the fasted state, compared with 53% and 83% after food. Time to maximum PT prolongation was delayed by 0.5 to 1.5 hours after food, with no relevant influence of food type. No significant difference in C(max) and AUC was observed with coadministration of BAY 59-7939 and ranitidine or antacid.

Peng Jiang - One of the best experts on this subject based on the ideXlab platform.

  • influence of electrolytes on the thixotropy of ferric Aluminum Magnesium Hydroxide montmorillonite suspensions
    Journal of Dispersion Science and Technology, 2003
    Co-Authors: Wanguo Hou, Xiaonan Dai, Peng Jiang
    Abstract:

    The thixotropy of suspensions consisting of ferric Aluminum Magnesium Hydroxide (Fe‐Al‐Mg‐MMH) and Na‐montmorillonite (MT) is examined with special emphasis on the influence of electrolytes. When N...

  • influence of electrolytes on the thixotropy of ferric Aluminum Magnesium Hydroxide montmorillonite suspensions
    Journal of Dispersion Science and Technology, 2003
    Co-Authors: Shuping Li, Peng Jiang
    Abstract:

    Abstract The thixotropy of suspensions consisting of ferric Aluminum Magnesium Hydroxide (Fe‐Al‐Mg‐MMH) and Na‐montmorillonite (MT) is examined with special emphasis on the influence of electrolytes. When NaCl or MgCl2 is added into the Fe‐Al‐Mg‐MMH/MT suspension, the thixotropy of the suspension may change (if positive) from positive and complex into negative, but NaCl or MgCl2 can't alter the thixotropic type of a negatively thixotropic suspension. When AlCl3 was added to positive thixotropic system can be transformed to a complex one, whereas a complex and negative thixotropic suspension remains unchanged, for additions less than 0.01 mol/L; when the addition level of AlCl3 increases, all types of thixotropic systems are changed to non‐thixotropic. In addition, NaCl and MgCl2 make the initial viscosity measured after cessation of intensive shearing increase, but the value of the viscosity decreased rapidly with time. The equilibrium viscosity of the suspension decreased gradually with increasing concen...